Cargando…
STRN-ALK Fusion in a Case of Malignant Peritoneal Mesothelioma: Mixed Response to Crizotinib, Mode of Resistance, and Brigatinib Sequential Therapy
Autores principales: | Gerthofer, Valeria, Scheiter, Alexander, Lüke, Florian, Keil, Felix, Utpatel, Kirsten, Pöhmerer, Laura-Maria-Giovanna, Seitz, Johannes, Niessen, Christoph, Ignatov, Atanas, Dietmaier, Wolfgang, Calvisi, Diego F., Evert, Matthias, Ortmann, Olaf, Seitz, Stephan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462007/ https://www.ncbi.nlm.nih.gov/pubmed/34568722 http://dx.doi.org/10.1200/PO.21.00184 |
Ejemplares similares
-
STRN-ALK Rearranged Malignant Peritoneal Mesothelioma With Dramatic Response Following Ceritinib Treatment
por: Rüschoff, Jan H., et al.
Publicado: (2019) -
Coexistence of a novel STRN-ALK, NBEA-ALK double-fusion in an ovarian malignant mesothelioma patient: a case report and review
por: Wu, Xiao, et al.
Publicado: (2023) -
Identification of a Recurrent STRN/ALK Fusion in Thyroid Carcinomas
por: Pérot, Gaëlle, et al.
Publicado: (2014) -
STRN-ALK, A Novel In-Frame Fusion With Response to Alectinib
por: Nagasaka, Misako, et al.
Publicado: (2020) -
The role of brigatinib in crizotinib-resistant non-small cell lung cancer
por: Mezquita, Laura, et al.
Publicado: (2018)